December 6, 2012 Amorfix and Cangene Collaborate on Development of Therapeutic Antibodies for Oncology
November 21, 2012 Amorfix Begins Offering EP-AD Diagnostic for Alzheimer's Disease Drug Development
November 14, 2012 Amorfix Announces Second Quarter Fiscal 2013 Result
November 7, 2012 Amorfix Research and Development Programs Leading the Way for New Therapeutics For ALS
November 1, 2012 Amorfix Antibodies Development Program For ALS To Be Presented At Leading ALS Conference
October 18, 2012 Amorfix CEO Dr. Robert Gundel to Present At The New York Society of Security Analysts Annual Conference
October 3, 2012 Amorfix Announces Retirement of Dr. Philippe Couillard
September 20, 2012 Amorfix Begins Preclinical Studies with Tumor Specific Antibodies For Treatment of Ovarian Cancer
September 7, 2012 Amorfix Chief Scientific Officer To Present at the New Genes, Potential Treatments and Models for ALS Drug Development Conference
August 27, 2012 Amorfix To Present At the Rodman & Renshaw 14th Annual Global Investment Conference
August 15, 2012 Amorfix Alzheimer's Disease Diagnostic Test Allows Accurate Identification of Early Stages of Alzheimer's Disease
August 14, 2012 Amorfix Announces First Quarter 2013 Results
June 28, 2012 Amorfix To Present Latest Data From Human Alzheimer's Disease Diagnostic Test At AAIC, Showing Ability To Accurately Identify Early-Stage Patients
June 22, 2012 Amorfix Announces Fiscal 2012 Year End Results
June 7, 2012 Amorfix Completes Licensing of Alzheimer's Disease Preclinical Assay to JSW Life Sciences
May 16, 2012 Amorfix Announces The Development Of Antibodies That Bind to Misfolded Fas Receptor Protein As A Potential Treatment For Cancer
May 14, 2012 Amorfix Closes Private Placement Offering
May 08, 2012 Amorfix Announces Private Placement
May 1, 2012 Amorfix To Collaborate With World Leader In Prion Diagnostic Research
April 17, 2012 Amorfix Chief Scientific Officer Receives Genome BC Award For Scientific Excellence
April 4, 2012 Amorfix Establishes Proof of Concept Of Lead Tumor-Specific Antibody For The Treatment Of Ovarian Cancer
March 12, 2012 Amorfix Acquires SOD1 Technology and Provides Update on Financing
February 27, 2012 Amorfix to Present at BioPartnering North America
February 23, 2012 Amorfix Appoints Lynda Covello Vice President of Strategic Alliances
February 10, 2012 Amorfix Announces Third Quarter Fiscal 2012 Results
January 23, 2012 Amorfix To Participate In Canadian Neuroscience Partnering Trade Mission To Europe
January 18, 2012 Amorfix Closes First Tranche Of Private Placement
January 9, 2012 Amorfix and JSW Sign LOI For Exclusive Worldwide License of Preclinical Alzheimer's Disease Diagnostic Technology